Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 28:12:1179554918782475.
doi: 10.1177/1179554918782475. eCollection 2018.

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

B J Srinivasa  1 , Bhanu Prakash Lalkota  1 , Girish Badarke  1 , Diganta Hazarika  2 , Nasiruddin Mohammad  2 , Sulav Sapkota  1 , Mansi Khanderia  1 , D Tousif  1 , Raghavendra Rao  3 , Amritanshu Ram  3 , Shekar Patil  1 , Radheshyam Naik  1
Affiliations

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

B J Srinivasa et al. Clin Med Insights Oncol. .

Abstract

Background: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients with MBC.

Methods: In this study, a total of 45 eligible patients with MBC who received eribulin in HCG Cancer Speciality Center from November 2014 to March 2016 were prospectively analyzed. Breslow (generalized Wilcoxon) survival analysis was carried out for progression-free survival and for overall survival. Patients were excluded if they had not taken treatment for 3 cycles and defaulted/expired during the treatment.

Results: In this study, median age of patients was 52 years. A total of 27 (60%) patients had estrogen receptor and progesterone receptor (PR) positive primary tumors, whereas HER2 was overexpressed or amplified in 7 (15.6%); a triple negative subtype was recorded in 13 patients (28.9%). Regarding toxicity, 30 patients (66.67%) tolerated treatment well and 3 patients (6.67%) got anemia, 6 patients (13.3%) experienced neutropenia, and 7 (15.62%) patients had neurological toxicity. About 14 (31.1%) patients showed PR, 12 (26.7%) patients had stable disease (SD), whereas 19 (42.25%) patients showed progression disease (PD). Response evaluation at 6 cycles was possible in 18 patients and revealed that 4 (22.5%) patients showed PR, 10 (55.5%) patients had SD, whereas 4 (22.2%) patients had PD. Progression-free survival of the overall study population was 3.95 months.

Conclusions: Eribulin mesylate is efficacious and tolerable chemotherapy as second- and third-line treatment options for MBC.

Keywords: Breast cancer; cancer chemotherapy; eribulin mesylate; overall survival; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Graph to represent survival over time in months.
See this image and copyright information in PMC

References

    1. International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer; 2013. http://globocon.iarc.fr
    1. Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac J Cancer Prev. 2016;17:47–52. - PubMed
    1. Ro J, Cheng FT, Sriuranpong V, et al. Patient management with eribulin in metastatic breast cancer: a clinical practice guide. J Breast Cancer. 2016;19:8–17. - PMC - PubMed
    1. Garrone O, Montemurro F, Saggia C, et al. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicentre retrospective study of eribulin in real life. Springerplus. 2016;5:59. - PMC - PubMed
    1. Thippeswamy R, Patil S, Shashidara HP, Satheesh CT, Vittal H, Mishra S. Eribulin mesylate in Indian patients: a single center experience. Indian J Cancer. 2015;52:297–298. - PubMed

LinkOut - more resources